An Observational Study of Ocrelizumab Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (VERISMO Study)

First published 31/07/2019

Last updated 14/03/2024

EU PAS number:

EUPAS30752

Study

Ongoing

Documents

Study protocol

Initial protocol

Protocol BA39731 OCREVUS v1_Redacted_final

English (1.95 MB - PDF) View document

Updated protocol

Prot BA39731 ocrelizumab v3, Published Output-1_Redacted

First published: 22/02/2024

English (1.42 MB - PDF) View document

Study results

Study report

Other information

Secondary tabs